Melanoma-associated antigens as messenger RNA detection markers for melanoma

被引:0
|
作者
Sarantou, T
Chi, DDJ
Garrison, DA
Conrad, AJ
Schmid, P
Morton, DL
Hoon, DSB
机构
[1] ST JOHNS HOSP,JOHN WAYNE CANC INST,SANTA MONICA,CA 90404
[2] CTR HLTH,SANTA MONICA,CA 90404
[3] NATL INST GENET,LOS ANGELES,CA 90054
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Melanoma is heterogeneous for its biological properties and melanoma-associated antigens (MAAs), This diversity is partially observed in the expression of the MAAs involved with the melanin synthesis pathway, We therefore developed a sensitive multimarker reverse transcription-PCR plus Southern blot assay using five MAAs as molecular markers to detect primary and metastatic melanoma cells, Melanoma cell lines, melanocytes (cultured), primary and metastatic malignant melanoma tissues, and blood from patients with American Joint Committee on Cancer stage I-IV melanoma were assessed for tyrosinase, tyrosinase-related proteins 1 and 2, Pmel 17, and MART-1/melan-A. All of the MAA mRNA markers were expressed in 100% of melanoma cell lines and cultured melanocytes, 74% of primary and metastatic tumors (excluding tumor-draining lymph nodes), 43% of tumor-involved lymph nodes, and 43% of patients' bloods, Hypomelanotic melanoma tissues expressed a lower frequency of individual. mRNA markers, Overall, at least one mRNA marker was expressed in more than 86% of specimens assayed, Normal tissue specimens from patients and blood from normal volunteer donors were negative for MAA mRNA expression, The multimarker MAA reverse transcription-PCR plus Southern blot analysis was more reliable and sensitive than a single-molecular marker assay for the detection of melanoma cells. This molecular assay can also provide information on MAA mRNA expression of metastatic melanoma cells that may assist in monitoring the therapeutic efficacy of active specific immunotherapy toward specific MAA-bearing melanomas.
引用
收藏
页码:1371 / 1376
页数:6
相关论文
共 50 条
  • [11] PURIFICATION OF SOLUBLE HUMAN MELANOMA-ASSOCIATED ANTIGENS
    ROTH, JA
    SLOCUM, HK
    PELLEGRINO, MA
    HOLMES, EC
    REISFELD, RA
    CANCER RESEARCH, 1976, 36 (07) : 2360 - 2364
  • [12] MELANOMA-ASSOCIATED ANTIGENS - PROSPECTS FOR CLINICAL USE
    LEJEUNE, FJ
    LIBERT, A
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1985, 21 (12): : 1433 - 1438
  • [13] DETECTION AND PURIFICATION OF HUMAN MELANOMA-ASSOCIATED CELL-SURFACE ANTIGENS
    MCCABE, RP
    FRUGIS, L
    FERRONE, S
    KERN, D
    REISFELD, RA
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1978, 19 (MAR): : 206 - 206
  • [14] Melanoma-associated tumor antigens and their clinical relevance to immunotherapy
    GattoniCelli, S
    Cole, DJ
    SEMINARS IN ONCOLOGY, 1996, 23 (06) : 754 - 758
  • [15] ANTIBODIES TO MELANOMA-ASSOCIATED ANTIGENS IN BENIGN MELANOCYTIC DISORDERS
    NANESS, J
    SHEIKH, K
    GUPTA, R
    REA, T
    FRIOU, G
    MORTON, D
    LEVAN, N
    CLINICAL RESEARCH, 1976, 24 (03): : A266 - A266
  • [16] HUMAN MELANOMA-ASSOCIATED GLYCOLIPID ANTIGENS IMMUNOGENEIC IN MAN
    JOHNSTON, D
    BYSTRYN, JC
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1984, 25 (MAR): : 277 - 277
  • [17] T-cell recognition of melanoma-associated antigens
    Castelli, C
    Rivoltini, L
    Andreola, G
    Carrabba, M
    Renkvist, N
    Parmiani, G
    JOURNAL OF CELLULAR PHYSIOLOGY, 2000, 182 (03) : 323 - 331
  • [18] MELANOMA-ASSOCIATED ANTIGENS IN DEPARAFFINIZED TISSUE-SECTIONS
    SLOAN, JB
    SUTHIPINITTHARM, P
    SOLTANI, K
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1986, 87 (05) : 678 - 678
  • [19] DEMONSTRATION OF HUMAN MELANOMA-ASSOCIATED ANTIGENS IN HISTOLOGICAL SECTIONS
    HELLSTROM, I
    HELLSTROM, KE
    FEDERATION PROCEEDINGS, 1983, 42 (03) : 565 - 565
  • [20] Mitotilin and titin as target antigens in melanoma-associated retinopathy
    Pfoehler, Claudia
    Preuss, Klaus-Dieter
    Tilgen, Wolfgang
    Stark, Alexandra
    Regitz, Evi
    Fadle, Natalie
    Pfreundschuh, Michael
    INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (04) : 788 - 795